# ANGIOGENESIS: A CONTROL POINT IN ANIMAL AND HUMAN TUMORS

> **NIH NIH R01** · BOSTON CHILDREN'S HOSPITAL · 1989 · $325,792

## Abstract

The long-term goal of the Principal Investigator is the exploration of
three questions:  (1) What is the role of angiogenesis in tumor growth?
(2) How is tumor angiogenesis mediated?  (3) How can tumor angiogenesis bbe
inhibited?

The principal investigator has recently discovered a new class of steroids
which inhibit angiogenesis in the presence of heparin.  These are named
"angiostatic" steroids.  There is a sub-set of these steroids which have no
other known function except for the inhibition of angiogenesis.
Angiostatic steroids are normally present at low levels in the circulation,
and they can now be made synthetically.

The overall objective of this grant proposal is two-fold:  (1) to delineate
the mechanism of action of angiostatic steroids at the cellular and
molecular level; and (2) to test these compounds in tumor-bearing mice, so
that a Phase I clinical trial can be designed.

An additional objective is to test our hypothesis that the high survival
rate and low metastatic rate in patients with a thin cutaneous melanoma
(e.g., less than 0.76 mm), is because these lesions are avascular.

## Key facts

- **NIH application ID:** 3175270
- **Project number:** 5R01CA037395-08
- **Recipient organization:** BOSTON CHILDREN'S HOSPITAL
- **SAM.gov UEI:** Z1L9F1MM1RY3
- **Principal Investigator:** JUDAH FOLKMAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $325,792
- **Award type:** 5
- **Project period:** 1983-01-01 → 1990-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3175270

## Citation

> US National Institutes of Health, RePORTER application 3175270, ANGIOGENESIS: A CONTROL POINT IN ANIMAL AND HUMAN TUMORS (5R01CA037395-08). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3175270. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*